Innovative Pressure Ulcer Treatment Product Achieves International Patent Status

Share Article

CMD Innovations is pleased to announce that its revolutionary pressure ulcer prevention system has reached final patent approval by the European Patent Office (EPO).

CMD Innovations is pleased to announce that its revolutionary pressure ulcer prevention system has reached final patent approval by the European Patent Office (EPO).

The patent grant by the EPO follows the award of US patent status (2014) and allows CMD Innovations to expand to international scale its mission to prevent the conditions that lead to pressure ulcers.

Pressure ulcers in the U.S. affect an estimated 2.5 million patients resulting in an estimated 60,000 deaths. Treatment of hospital-acquired pressure ulcers is not reimbursable by Medicare, which creates a financial drain estimated to exceed 10 billion dollars per year in the U.S. This is a cost on top of the unnecessary pain and suffering of patients and their families.

CMD Innovations was founded to alleviate the conditions that lead to the formation of pressure ulcers. Its founder, Mike Dennis, has extensive experience solving similar tissue problems for pilots in the aviation industry, supplying to all three branches of the United States military, the Coast Guard, and civilian corporations such as Boeing and Lockheed Martin.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ryan Kunes
Visit website